Detalhe da pesquisa
1.
Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study.
J Headache Pain
; 22(1): 113, 2021 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592919
2.
Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Int Psychogeriatr
; 32(2): 267-277, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31134870
3.
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Cephalalgia
; 39(8): 931-944, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31104507
4.
Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.
Neurol Ther
; 12(2): 651-668, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848008
5.
Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention.
J Manag Care Spec Pharm
; 29(12): 1321-1330, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38058137
6.
Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™.
J Pain Res
; 16: 357-371, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762367
7.
Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany.
Curr Med Res Opin
; 39(12): 1637-1647, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37615206
8.
Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis.
Adv Ther
; 39(10): 4544-4555, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930126
9.
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.
J Med Econ
; 25(1): 630-639, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510376
10.
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Clin Drug Investig
; 42(3): 263-275, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041159
11.
The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making.
Patient
; 15(5): 551-564, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435572
12.
Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study.
Patient
; 15(1): 93-108, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34131880
13.
Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures.
Clinicoecon Outcomes Res
; 13: 647-660, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34285524
14.
Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
Adv Ther
; 38(8): 4442-4460, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264500
15.
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
Adv Ther
; 38(11): 5465-5483, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34542830
16.
Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia.
Patient Prefer Adherence
; 14: 1049-1064, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32612354
17.
A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe.
J Patient Rep Outcomes
; 4(1): 53, 2020 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32632891
18.
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet Neurol
; 19(10): 814-825, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949542
19.
Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.
Alzheimers Res Ther
; 12(1): 154, 2020 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33208190
20.
Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Neurology
; 93(5): e508-e517, 2019 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270220